1 891 145 EFFECT OF YOGA-BASED INTERVENTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. BACKGROUND: INFLAMMATORY BOWEL DISEASE (IBD) IS A CHRONIC ILLNESS CHARACTERIZED BY GROSS INFLAMMATION IN THE GASTROINTESTINAL TRACT THAT CAN RESULT IN SYMPTOMS SUCH AS ABDOMINAL PAIN, CRAMPING, DIARRHEA, AND BLOODY STOOLS. IBD IS BELIEVED TO BE INFLUENCED BY PSYCHOLOGICAL FACTORS SUCH AS STRESS AND ANXIETY. THEREFORE, A YOGA INTERVENTION THAT REDUCES STRESS AND ANXIETY MAY BE AN EFFECTIVE COMPLEMENTARY TREATMENT FOR THESE DISORDERS. MATERIAL AND METHODS: A TOTAL OF 100 IBD PATIENTS [ULCERATIVE COLITIS (UC) N = 60 AND CROHN'S DISEASE (CD) N = 40] DURING THE CLINICAL REMISSION PHASE OF DISEASE WERE INCLUDED IN THE STUDY. THESE PATIENTS WERE ALLOCATED RANDOMLY TO EITHER THE YOGA GROUP THAT UNDERWENT AN 8-WEEK YOGA INTERVENTION (PHYSICAL POSTURES, PRANAYAMA, AND MEDITATION) 1- HOUR/DAY IN ADDITION TO STANDARD MEDICAL THERAPY (UC, N = 30; CD, N = 20) OR THE CONTROL GROUP (UC, N = 30; CD N = 20), WHICH CONTINUED WITH STANDARD MEDICAL THERAPY ALONE. THE MAIN OUTCOME MEASURES WERE CARDIOVASCULAR AUTONOMIC FUNCTIONS, SERUM EOSINOPHILIC CATIONIC PROTEIN, INTERLEUKIN- 2 SOLUBLE RECEPTORS, SPEILBERGER'S STATE TRAIT ANXIETY INVENTORY (STAI) SCORES, AND CLINICAL SYMPTOMS. RESULTS: BEFORE THE INTERVENTION, ALL THE OUTCOME MEASURES WERE COMPARABLE IN THE TWO GROUPS. AFTER THE 8-WEEK YOGA INTERVENTION, FEWER UC PATIENTS REPORTED ARTHRALGIA. THE NUMBER OF PATIENTS REPORTING INTESTINAL COLIC PAIN IN THE CONTROL GROUP WAS HIGHER. STATE AND TRAIT ANXIETY LEVELS WERE SIGNIFICANTLY REDUCED IN PATIENTS WITH UC. HOWEVER, NO SIGNIFICANT CHANGES WERE OBSERVED IN CARDIOVASCULAR AUTONOMIC FUNCTIONS, EOSINOPHILIC CATIONIC PROTEINS, OR INTERLEUKIN-2 SOLUBLE RECEPTORS. CONCLUSIONS: A SIMPLIFIED YOGA-BASED REGIMEN IS A SAFE AND EFFECTIVE COMPLEMENTARY CLINICAL TREATMENT MODALITY FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE DURING THE CLINICAL REMISSION PHASE. 2015 2 607 24 DEVELOPMENT OF A CHEWABLE TABLET FROM DUGDHAMALAKYADI YOGA: AN AYURVEDIC PREPARATION. BACKGROUND: AMALAKI (EMBELICA OFFICINALIS GAERTN.) IS ONE OF THE MOST CELEBRATED HERBS IN THE INDIAN SYSTEM OF TRADITIONAL MEDICINE. IT IS ONE OF THE BEST RASAYANA-S (HEALTH PROMOTING) DRUG. IN DUGDHAMALAKYADI YOGA, AMALAKI (EMBELICA OFFICINALIS GAERTN.) POWDER IS ADMINISTERED ALONG WITH MILK IN CASE OF SVARABHANGA (HOARSENESS OF VOICE). HERE AN ATTEMPT IS MADE TO CONVERT THIS FORMULATION INTO CHEWABLE TABLET WITHOUT ALTERING ITS PROPERTY TO IMPROVE ITS PALATABILITY, SHELF LIFE AND FIXATION OF PROPER THERAPEUTIC DOSE. METHODOLOGY: CHEWABLE TABLETS WERE PREPARED BY WET GRANULATION METHOD. HERE, AMALAKI POWDER WAS PREPARED INITIALLY AND IT WAS MIXED WITH ADDITIVES AND PRESERVATIVES. GRANULES WERE PREPARED FROM THIS MIXTURE BY ADDING BINDING AGENT, FINALLY COMPRESSED IN TO TABLETS. RESULTS AND CONCLUSION: THE PHYSICO-CHEMICAL ANALYSIS OF AMALAKI STANDARD ARE: FOREIGN MATTER-NIL, ACID INSOLUBLE ASH-0.51%W/W, WATER SOLUBLE ASH-2.01% W/W, ALCOHOLIC EXTRACTIVES-44.48%, AQUEOUS EXTRACTIVES 67.52%, PH-3.1, MOISTURE CONTENT-8.19%. QUALITY CONTROL TEST FOR CHEWABLE TABLET WAS CARRIED OUT AND FOUND SATISFACTORY WITH GENERAL CHARACTERISTICS OF TABLET VIZ. HARDNESS 1.8, DISINTEGRATION TIME 15-20 MIN, FRIABILITY 0.5%, WEIGHT VARIATION +/- 3%. THE TLC OF AMALAKI POWDER SHOWED 3 SPOTS WITH RF VALUE 0.14, 0.4, AND 0.73 AND THE CHEWABLE TABLETS SHOWED 2 SPOTS WITH RF VALUE 0.31 AND 0.89 UNDER 254 NM. THE ADAPTATION OF MODERN TECHNIQUES OR METHODS TO CONVERT THE AYURVEDIC FORMULATIONS WITHOUT ALTERING ITS THERAPEUTIC PROPERTY IS NECESSARY TO MADE THEM SUITABLE FOR THE PRESENT TRENDS OF NEWER DRUG DELIVERY DOSAGE FORMS. 2012 3 1881 26 REDUCED HYPOXIC VENTILATORY RESPONSE WITH PRESERVED BLOOD OXYGENATION IN YOGA TRAINEES AND HIMALAYAN BUDDHIST MONKS AT ALTITUDE: EVIDENCE OF A DIFFERENT ADAPTIVE STRATEGY? YOGA INDUCES LONG-TERM CHANGES IN RESPIRATORY FUNCTION AND CONTROL. WE TESTED WHETHER IT REPRESENTS A SUCCESSFUL STRATEGY FOR HIGH-ALTITUDE ADAPTATION. WE COMPARED VENTILATORY, CARDIOVASCULAR AND HEMATOLOGICAL PARAMETERS IN: 12 CAUCASIAN YOGA TRAINEES AND 12 CONTROL SEA-LEVEL RESIDENTS, AT BASELINE AND AFTER 2-WEEK EXPOSURE TO HIGH ALTITUDE (PYRAMID LABORATORY, NEPAL, 5,050 M), 38 ACTIVE LIFESTYLE HIGH-ALTITUDE NATIVES (SHERPAS) AND 13 CONTEMPLATIVE LIFESTYLE HIGH-ALTITUDE NATIVES WITH PRACTICE OF YOGA-LIKE RESPIRATORY EXERCISES (BUDDHIST MONKS) STUDIED AT 5,050 M. AT BASELINE, HYPOXIC VENTILATORY RESPONSE (HVR), RED BLOOD CELL COUNT AND HEMATOCRIT WERE LOWER IN CAUCASIAN YOGA TRAINEES THAN IN CONTROLS. AFTER 14 DAYS AT ALTITUDE, YOGA TRAINEES SHOWED SIMILAR OXYGEN SATURATION, BLOOD PRESSURE, RR INTERVAL COMPARED TO CONTROLS, BUT LOWER HVR (-0.44 +/- 0.08 VS. -0.98 +/- 0.21 L/MIN/M/%SAO(2), P < 0.05), MINUTE VENTILATION (8.3 +/- 0.9 VS. 10.8 +/- 1.6 L/MIN, P < 0.05), BREATHING RATE (INDICATING HIGHER VENTILATORY EFFICIENCY), AND LOWER RED BLOOD CELL COUNT, HEMOGLOBIN, HEMATOCRIT, ALBUMIN, ERYTHROPOIETIN AND SOLUBLE TRANSFERRIN RECEPTORS. HYPOXIC VENTILATORY RESPONSE IN MONKS WAS LOWER THAN IN SHERPAS (-0.23 +/- 0.05 VS. -0.63 +/- 0.09 L/MIN/M/%SAO(2), P < 0.05); VALUES WERE SIMILAR TO BASELINE DATA OF YOGA TRAINEES AND CAUCASIAN CONTROLS, RESPECTIVELY. RED BLOOD CELL COUNT AND HEMATOCRIT WERE LOWER IN MONKS AS COMPARED TO SHERPAS. IN CONCLUSION, CAUCASIAN SUBJECTS PRACTICING YOGA MAINTAIN A SATISFACTORY OXYGEN TRANSPORT AT HIGH ALTITUDE, WITH MINIMAL INCREASE IN VENTILATION AND WITH REDUCED HEMATOLOGICAL CHANGES, RESEMBLING HIMALAYAN NATIVES. RESPIRATORY ADAPTATIONS INDUCED BY THE PRACTICE OF YOGA MAY REPRESENT AN EFFICIENT STRATEGY TO COPE WITH ALTITUDE-INDUCED HYPOXIA. 2007 4 2768 47 YOGA REDUCES INFLAMMATORY SIGNALING IN FATIGUED BREAST CANCER SURVIVORS: A RANDOMIZED CONTROLLED TRIAL. BACKGROUND: YOGA IS A POPULAR MIND-BODY THERAPY THAT HAS DEMONSTRATED BENEFICIAL EFFECTS ON PSYCHOLOGICAL, BEHAVIORAL, AND FUNCTIONAL OUTCOMES. HOWEVER, FEW STUDIES HAVE INVESTIGATED EFFECTS ON INFLAMMATORY PROCESSES. THIS STUDY TESTED THE HYPOTHESIS THAT AN IYENGAR YOGA INTERVENTION SPECIFICALLY DESIGNED FOR FATIGUED BREAST CANCER SURVIVORS WOULD LEAD TO DECREASES IN INFLAMMATION-RELATED GENE EXPRESSION AND CIRCULATING MARKERS OF PROINFLAMMATORY CYTOKINE ACTIVITY. METHODS: BREAST CANCER SURVIVORS WITH PERSISTENT CANCER-RELATED FATIGUE WERE RANDOMIZED TO A 12-WEEK IYENGAR YOGA INTERVENTION (N=16) OR A 12-WEEK HEALTH EDUCATION CONTROL CONDITION (N=15). BLOOD SAMPLES WERE COLLECTED AT BASELINE, POST-INTERVENTION, AND AT A 3-MONTH FOLLOW-UP FOR GENOME-WIDE TRANSCRIPTIONAL PROFILING AND BIOINFORMATIC ANALYSES. PLASMA INFLAMMATORY MARKERS AND SALIVARY CORTISOL WERE ALSO ASSESSED. RESULTS: IN PROMOTER-BASED BIOINFORMATICS ANALYSES, THE YOGA GROUP SHOWED REDUCED ACTIVITY OF THE PRO-INFLAMMATORY TRANSCRIPTION FACTOR NUCLEAR FACTOR KAPPA B (NF-KAPPAB), INCREASED ACTIVITY OF THE ANTI-INFLAMMATORY GLUCOCORTICOID RECEPTOR, AND REDUCED ACTIVITY OF CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB) FAMILY TRANSCRIPTION FACTORS RELATIVE TO CONTROLS (ALL PS<.05). THERE WAS ALSO A SIGNIFICANT INTERVENTION EFFECT ON THE SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TYPE II (STNF-RII), A MARKER OF TNF ACTIVITY; PLASMA LEVELS OF STNF-RII REMAINED STABLE IN THE YOGA GROUP, WHEREAS LEVELS OF THIS MARKER INCREASED IN THE HEALTH EDUCATION GROUP (P=.028). A SIMILAR, NON-SIGNIFICANT TREND WAS OBSERVED FOR THE INTERLEUKIN 1 RECEPTOR ANTAGONIST (P=.16). NO SIGNIFICANT CHANGES IN C REACTIVE PROTEIN (CRP), INTERLEUKIN 6 (IL-6), OR DIURNAL CORTISOL MEASURES WERE OBSERVED. CONCLUSIONS: A 12-WEEK RESTORATIVE IYENGAR YOGA INTERVENTION REDUCED INFLAMMATION-RELATED GENE EXPRESSION IN BREAST CANCER SURVIVORS WITH PERSISTENT FATIGUE. THESE FINDINGS SUGGEST THAT A TARGETED YOGA PROGRAM MAY HAVE BENEFICIAL EFFECTS ON INFLAMMATORY ACTIVITY IN THIS PATIENT POPULATION, WITH POTENTIAL RELEVANCE FOR BEHAVIORAL AND PHYSICAL HEALTH. 2014 5 508 33 COMPARATIVE EFFICACY OF A 12 WEEK YOGA-BASED LIFESTYLE INTERVENTION AND DIETARY INTERVENTION ON ADIPOKINES, INFLAMMATION, AND OXIDATIVE STRESS IN ADULTS WITH METABOLIC SYNDROME: A RANDOMIZED CONTROLLED TRIAL. THE PRESENT RANDOMIZED CONTROLLED TRIAL (RCT) EVALUATED THE COMPARATIVE EFFICACY OF 12 WEEK YOGA-BASED LIFESTYLE INTERVENTION (YBLI) AND DIETARY INTERVENTION (DI) ALONE ON ADIPOKINES, INFLAMMATION, AND OXIDATIVE STRESS IN INDIAN ADULTS WITH METABOLIC SYNDROME (MET S). A PARALLEL, TWO ARM, RCT WAS CONDUCTED IN INTEGRAL HEALTH CLINIC (IHC), ALL INDIA INSTITUTE OF MEDICAL SCIENCES, INDIA FROM 2012 TO 2014. IHC IS AN OUTPATIENT FACILITY CONDUCTING YBLI PROGRAMS FOR PREVENTION AND MANAGEMENT OF CHRONIC DISEASES. TWO HUNDRED SIXTY MEN AND WOMEN (20-45 YEARS) VISITING THE OUTPATIENT DEPARTMENT OF A TERTIARY CARE HOSPITAL WERE DIAGNOSED WITH MET S AND RANDOMIZED 1:1 TO RECEIVE 12 WEEK YBLI (N = 130) OR DI (N = 130). PRIMARY OUTCOMES WERE CHANGE IN PLASMA LEVELS OF ADIPOKINES (LEPTIN, ADIPONECTIN, AND LEPTIN:ADIPONECTIN RATIO), MARKERS OF INFLAMMATION (TUMOR NECROSIS FACTOR [TNF]-ALPHA, INTERLEUKIN [IL]-6), MARKERS OF OXIDATIVE STRESS (THIOBARBITURIC ACID REACTIVE SUBSTANCES [TBARS], 8-HYDROXY-2'-DEOXYGUANOSINE [8-OHDG], AND SUPEROXIDE DISMUTASE [SOD]) MEASURED AT BASELINE, 2 WEEKS, AND 12 WEEKS. YBLI GROUP SHOWED A SIGNIFICANT DECREASE IN LEPTIN, LEPTIN:ADIPONECTIN RATIO, IL-6, 8-OHDG, AND TBARS LEVELS, WHEREAS THERE WAS A SIGNIFICANT INCREASE IN ADIPONECTIN AND SOD LEVELS. NO SIGNIFICANT CHANGES WERE NOTICED IN DI ALONE GROUP. YBLI SHOWED SIGNIFICANTLY GREATER REDUCTION IN TBARS LEVELS THAN IN DI GROUP, SUGGESTIVE OF REDUCED OXIDATIVE STRESS IN ADULTS WITH MET S. A 12 WEEK YBLI HAD A POSITIVE IMPACT ON OXIDATIVE STRESS VERSUS DI ALONE IN ADULTS WITH MET S. 2019 6 2821 56 YOGA TREATMENT FOR CHRONIC NON-SPECIFIC LOW BACK PAIN. BACKGROUND: NON-SPECIFIC LOW BACK PAIN IS A COMMON, POTENTIALLY DISABLING CONDITION USUALLY TREATED WITH SELF-CARE AND NON-PRESCRIPTION MEDICATION. FOR CHRONIC LOW BACK PAIN, CURRENT GUIDELINES STATE THAT EXERCISE THERAPY MAY BE BENEFICIAL. YOGA IS A MIND-BODY EXERCISE SOMETIMES USED FOR NON-SPECIFIC LOW BACK PAIN. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA FOR TREATING CHRONIC NON-SPECIFIC LOW BACK PAIN, COMPARED TO NO SPECIFIC TREATMENT, A MINIMAL INTERVENTION (E.G. EDUCATION), OR ANOTHER ACTIVE TREATMENT, WITH A FOCUS ON PAIN, FUNCTION, AND ADVERSE EVENTS. SEARCH METHODS: WE SEARCHED CENTRAL, MEDLINE, EMBASE, FIVE OTHER DATABASES AND FOUR TRIALS REGISTERS TO 11 MARCH 2016 WITHOUT RESTRICTION OF LANGUAGE OR PUBLICATION STATUS. WE SCREENED REFERENCE LISTS AND CONTACTED EXPERTS IN THE FIELD TO IDENTIFY ADDITIONAL STUDIES. SELECTION CRITERIA: WE INCLUDED RANDOMIZED CONTROLLED TRIALS OF YOGA TREATMENT IN PEOPLE WITH CHRONIC NON-SPECIFIC LOW BACK PAIN. WE INCLUDED STUDIES COMPARING YOGA TO ANY OTHER INTERVENTION OR TO NO INTERVENTION. WE ALSO INCLUDED STUDIES COMPARING YOGA AS AN ADJUNCT TO OTHER THERAPIES, VERSUS THOSE OTHER THERAPIES ALONE. DATA COLLECTION AND ANALYSIS: TWO AUTHORS INDEPENDENTLY SCREENED AND SELECTED STUDIES, EXTRACTED OUTCOME DATA, AND ASSESSED RISK OF BIAS. WE CONTACTED STUDY AUTHORS TO OBTAIN MISSING OR UNCLEAR INFORMATION. WE EVALUATED THE OVERALL CERTAINTY OF EVIDENCE USING THE GRADE APPROACH. MAIN RESULTS: WE INCLUDED 12 TRIALS (1080 PARTICIPANTS) CARRIED OUT IN THE USA (SEVEN TRIALS), INDIA (THREE TRIALS), AND THE UK (TWO TRIALS). STUDIES WERE UNFUNDED (ONE TRIAL), FUNDED BY A YOGA INSTITUTION (ONE TRIAL), FUNDED BY NON-PROFIT OR GOVERNMENT SOURCES (SEVEN TRIALS), OR DID NOT REPORT ON FUNDING (THREE TRIALS). MOST TRIALS USED IYENGAR, HATHA, OR VINIYOGA FORMS OF YOGA. THE TRIALS COMPARED YOGA TO NO INTERVENTION OR A NON-EXERCISE INTERVENTION SUCH AS EDUCATION (SEVEN TRIALS), AN EXERCISE INTERVENTION (THREE TRIALS), OR BOTH EXERCISE AND NON-EXERCISE INTERVENTIONS (TWO TRIALS). ALL TRIALS WERE AT HIGH RISK OF PERFORMANCE AND DETECTION BIAS BECAUSE PARTICIPANTS AND PROVIDERS WERE NOT BLINDED TO TREATMENT ASSIGNMENT, AND OUTCOMES WERE SELF-ASSESSED. THEREFORE, WE DOWNGRADED ALL OUTCOMES TO 'MODERATE' CERTAINTY EVIDENCE BECAUSE OF RISK OF BIAS, AND WHEN THERE WAS ADDITIONAL SERIOUS RISK OF BIAS, UNEXPLAINED HETEROGENEITY BETWEEN STUDIES, OR THE ANALYSES WERE IMPRECISE, WE DOWNGRADED THE CERTAINTY OF THE EVIDENCE FURTHER.FOR YOGA COMPARED TO NON-EXERCISE CONTROLS (9 TRIALS; 810 PARTICIPANTS), THERE WAS LOW-CERTAINTY EVIDENCE THAT YOGA PRODUCED SMALL TO MODERATE IMPROVEMENTS IN BACK-RELATED FUNCTION AT THREE TO FOUR MONTHS (STANDARDIZED MEAN DIFFERENCE (SMD) -0.40, 95% CONFIDENCE INTERVAL (CI) -0.66 TO -0.14; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MEAN DIFFERENCE (MD) -2.18, 95% -3.60 TO -0.76), MODERATE-CERTAINTY EVIDENCE FOR SMALL TO MODERATE IMPROVEMENTS AT SIX MONTHS (SMD -0.44, 95% CI -0.66 TO -0.22; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD -2.15, 95% -3.23 TO -1.08), AND LOW-CERTAINTY EVIDENCE FOR SMALL IMPROVEMENTS AT 12 MONTHS (SMD -0.26, 95% CI -0.46 TO -0.05; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD -1.36, 95% -2.41 TO -0.26). ON A 0-100 SCALE THERE WAS VERY LOW- TO MODERATE-CERTAINTY EVIDENCE THAT YOGA WAS SLIGHTLY BETTER FOR PAIN AT THREE TO FOUR MONTHS (MD -4.55, 95% CI -7.04 TO -2.06), SIX MONTHS (MD -7.81, 95% CI -13.37 TO -2.25), AND 12 MONTHS (MD -5.40, 95% CI -14.50 TO -3.70), HOWEVER WE PRE-DEFINED CLINICALLY SIGNIFICANT CHANGES IN PAIN AS 15 POINTS OR GREATER AND THIS THRESHOLD WAS NOT MET. BASED ON INFORMATION FROM SIX TRIALS, THERE WAS MODERATE-CERTAINTY EVIDENCE THAT THE RISK OF ADVERSE EVENTS, PRIMARILY INCREASED BACK PAIN, WAS HIGHER IN YOGA THAN IN NON-EXERCISE CONTROLS (RISK DIFFERENCE (RD) 5%, 95% CI 2% TO 8%).FOR YOGA COMPARED TO NON-YOGA EXERCISE CONTROLS (4 TRIALS; 394 PARTICIPANTS), THERE WAS VERY-LOW-CERTAINTY EVIDENCE FOR LITTLE OR NO DIFFERENCE IN BACK-RELATED FUNCTION AT THREE MONTHS (SMD -0.22, 95% CI -0.65 TO 0.20; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD -0.99, 95% -2.87 TO 0.90) AND SIX MONTHS (SMD -0.20, 95% CI -0.59 TO 0.19; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD -0.90, 95% -2.61 TO 0.81), AND NO INFORMATION ON BACK-RELATED FUNCTION AFTER SIX MONTHS. THERE WAS VERY LOW-CERTAINTY EVIDENCE FOR LOWER PAIN ON A 0-100 SCALE AT SEVEN MONTHS (MD -20.40, 95% CI -25.48 TO -15.32), AND NO INFORMATION ON PAIN AT THREE MONTHS OR AFTER SEVEN MONTHS. BASED ON INFORMATION FROM THREE TRIALS, THERE WAS LOW-CERTAINTY EVIDENCE FOR NO DIFFERENCE IN THE RISK OF ADVERSE EVENTS BETWEEN YOGA AND NON-YOGA EXERCISE CONTROLS (RD 1%, 95% CI -4% TO 6%).FOR YOGA ADDED TO EXERCISE COMPARED TO EXERCISE ALONE (1 TRIAL; 24 PARTICIPANTS), THERE WAS VERY-LOW-CERTAINTY EVIDENCE FOR LITTLE OR NO DIFFERENCE AT 10 WEEKS IN BACK-RELATED FUNCTION (SMD -0.60, 95% CI -1.42 TO 0.22; CORRESPONDING TO A CHANGE IN THE OSWESTRY DISABILITY INDEX OF MD -17.05, 95% -22.96 TO 11.14) OR PAIN ON A 0-100 SCALE (MD -3.20, 95% CI -13.76 TO 7.36). THERE WAS NO INFORMATION ON OUTCOMES AT OTHER TIME POINTS. THERE WAS NO INFORMATION ON ADVERSE EVENTS.STUDIES PROVIDED LIMITED EVIDENCE ON RISK OF CLINICAL IMPROVEMENT, MEASURES OF QUALITY OF LIFE, AND DEPRESSION. THERE WAS NO EVIDENCE ON WORK-RELATED DISABILITY. AUTHORS' CONCLUSIONS: THERE IS LOW- TO MODERATE-CERTAINTY EVIDENCE THAT YOGA COMPARED TO NON-EXERCISE CONTROLS RESULTS IN SMALL TO MODERATE IMPROVEMENTS IN BACK-RELATED FUNCTION AT THREE AND SIX MONTHS. YOGA MAY ALSO BE SLIGHTLY MORE EFFECTIVE FOR PAIN AT THREE AND SIX MONTHS, HOWEVER THE EFFECT SIZE DID NOT MEET PREDEFINED LEVELS OF MINIMUM CLINICAL IMPORTANCE. IT IS UNCERTAIN WHETHER THERE IS ANY DIFFERENCE BETWEEN YOGA AND OTHER EXERCISE FOR BACK-RELATED FUNCTION OR PAIN, OR WHETHER YOGA ADDED TO EXERCISE IS MORE EFFECTIVE THAN EXERCISE ALONE. YOGA IS ASSOCIATED WITH MORE ADVERSE EVENTS THAN NON-EXERCISE CONTROLS, BUT MAY HAVE THE SAME RISK OF ADVERSE EVENTS AS OTHER BACK-FOCUSED EXERCISE. YOGA IS NOT ASSOCIATED WITH SERIOUS ADVERSE EVENTS. THERE IS A NEED FOR ADDITIONAL HIGH-QUALITY RESEARCH TO IMPROVE CONFIDENCE IN ESTIMATES OF EFFECT, TO EVALUATE LONG-TERM OUTCOMES, AND TO PROVIDE ADDITIONAL INFORMATION ON COMPARISONS BETWEEN YOGA AND OTHER EXERCISE FOR CHRONIC NON-SPECIFIC LOW BACK PAIN. 2017 7 1374 45 IMPACT OF AN INTEGRATED YOGA THERAPY PROTOCOL ON INSULIN RESISTANCE AND GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. OBJECTIVE: DIABETES MELLITUS (DM), CHARACTERIZED BY CHRONIC HYPERGLYCEMIA, IS ATTRIBUTED TO RELATIVE INSULIN DEFICIENCY OR RESISTANCE, OR BOTH. STUDIES HAVE SHOWN THAT YOGA CAN MODULATE PARAMETERS OF INSULIN RESISTANCE. THE PRESENT STUDY EXPLORED THE POSSIBLE BENEFICIAL EFFECTS OF INTEGRATED YOGA THERAPY WITH REFERENCE TO GLYCEMIC CONTROL AND INSULIN RESISTANCE (IR) IN INDIVIDUALS WITH DIABETES MAINTAINED ON STANDARD ORAL MEDICAL CARE WITH YOGA THERAPY, COMPARED TO THOSE ON STANDARD ORAL MEDICAL CARE ALONE. METHODS: IN THIS STUDY, THE SUBJECTS ON YOGA INTERVENTION COMPRISED 35 TYPE 2 DIABETICS, AND AN EQUAL NUMBER OF VOLUNTEERS CONSTITUTED THE CONTROL GROUP. SUBJECTS RANGED IN AGE FROM 30 TO 70 YEARS, WITH HEMOGLOBIN A1C (HBA1C) TEST MORE THAN 7%, AND WERE MAINTAINED ON DIABETIC DIET AND ORAL HYPOGLYCEMIC AGENTS. BLOOD SAMPLES WERE DRAWN PRIOR TO AND AFTER 120 DAYS OF INTEGRATED YOGA THERAPY INTERVENTION. FASTING BLOOD GLUCOSE (FBG), POST-PRANDIAL BLOOD GLUCOSE (PPBG), HBA1C, INSULIN, AND LIPID PROFILE WERE ASSESSED IN BOTH THE INTERVENTION AND CONTROL GROUPS. RESULTS: THE INTERVENTION GROUP REVEALED SIGNIFICANT IMPROVEMENTS IN BODY MASS INDEX (BMI) (0.7 KG/M(2) MEDIAN DECREASE; P=0.001), FBG (20 MG/DL MEDIAN DECREASE; P<0.001), PPBG (33 MG/DL MEDIAN DECREASE; P<0.001), HBA1C (0.4% MEDIAN DECREASE; P<0.001), HOMEOSTATIC MODEL ASSESSMENT FOR INSULIN RESISTANCE (HOMA-IR) (1.2 MEDIAN DECREASE; P<0.001), CHOLESTEROL (13 MG/DL MEDIAN DECREASE, P=0.006), TRIACYLGLYCEROL (22 MG/DL MEDIAN DECREASE; P=0.027), LOW-DENSITY LIPOPROTEIN (6 MG/DL MEDIAN DECREASE; P=0.004), AND VERY-LOW-DENSITY LIPOPROTEIN LEVELS (4 MG/DL MEDIAN DECREASE; P=0.032). INCREASES IN HIGH-DENSITY LIPOPROTEIN AFTER 120 DAYS WERE NOT SIGNIFICANT (6 MG/DL MEDIAN INCREASE; P=0.15). HOWEVER, WHEN COMPARED TO CHANGES OBSERVED IN PATIENTS IN THE CONTROL GROUP, ALL THESE IMPROVEMENTS PROVED TO BE SIGNIFICANT. CONCLUSION: ADMINISTRATION OF INTEGRATED YOGA THERAPY TO INDIVIDUALS WITH DIABETES LEADS TO A SIGNIFICANT IMPROVEMENT IN GLYCEMIC CONTROL, INSULIN RESISTANCE, AND KEY BIOCHEMICAL PARAMETERS. 2022 8 2518 48 YOGA COMPARED TO NON-EXERCISE OR PHYSICAL THERAPY EXERCISE ON PAIN, DISABILITY, AND QUALITY OF LIFE FOR PATIENTS WITH CHRONIC LOW BACK PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. BACKGROUND: CHRONIC LOW BACK PAIN (CLBP) IS A COMMON AND OFTEN DISABLING MUSCULOSKELETAL CONDITION. YOGA HAS BEEN PROVEN TO BE AN EFFECTIVE THERAPY FOR CHRONIC LOW BACK PAIN. HOWEVER, THERE ARE STILL CONTROVERSIES ABOUT THE EFFECTS OF YOGA AT DIFFERENT FOLLOW-UP PERIODS AND COMPARED WITH OTHER PHYSICAL THERAPY EXERCISES. OBJECTIVE: TO CRITICALLY COMPARE THE EFFECTS OF YOGA FOR PATIENTS WITH CHRONIC LOW BACK PAIN ON PAIN, DISABILITY, QUALITY OF LIFE WITH NON-EXERCISE (E.G. USUAL CARE, EDUCATION), PHYSICAL THERAPY EXERCISE. METHODS: THIS STUDY WAS REGISTERED IN PROSPERO, AND THE REGISTRATION NUMBER WAS CRD42020159865. RANDOMIZED CONTROLLED TRIALS (RCTS) OF ONLINE DATABASES INCLUDED PUBMED, WEB OF SCIENCE, COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS, EMBASE WHICH EVALUATED EFFECTS OF YOGA FOR PATIENTS WITH CHRONIC LOW BACK PAIN ON PAIN, DISABILITY, AND QUALITY OF LIFE WERE SEARCHED FROM INCEPTION TIME TO NOVEMBER 1, 2019. STUDIES WERE ELIGIBLE IF THEY ASSESSED AT LEAST ONE IMPORTANT OUTCOME, NAMELY PAIN, BACK-SPECIFIC DISABILITY, QUALITY OF LIFE. THE COCHRANE RISK OF BIAS TOOL WAS USED TO ASSESS THE METHODOLOGICAL QUALITY OF INCLUDED RANDOMIZED CONTROLLED TRIALS. THE CONTINUOUS OUTCOMES WERE ANALYZED BY CALCULATING THE MEAN DIFFERENCE (MD) OR STANDARDIZED MEAN DIFFERENCE (SMD) WITH 95% CONFIDENCE INTERVALS (CI) ACCORDING TO WHETHER COMBINING OUTCOMES MEASURED ON DIFFERENT SCALES OR NOT. RESULTS: A TOTAL OF 18 RANDOMIZED CONTROLLED TRIALS WERE INCLUDED IN THIS META-ANALYSIS. YOGA COULD SIGNIFICANTLY REDUCE PAIN AT 4 TO 8 WEEKS (MD = -0.83, 95% CI = -1.19 TO -0.48, P<0.00001, I2 = 0%), 3 MONTHS (MD = -0.43, 95% CI = -0.64 TO -0.23, P<0.0001, I2 = 0%), 6 TO 7 MONTHS (MD = -0.56, 95% CI = -1.02 TO -0.11, P = 0.02, I2 = 50%), AND WAS NOT SIGNIFICANT IN 12 MONTHS (MD = -0.52, 95% CI = -1.64 TO 0.59, P = 0.36, I2 = 87%) COMPARED WITH NON-EXERCISE. YOGA WAS BETTER THAN NON-EXERCISE ON DISABILITY AT 4 TO 8 WEEKS (SMD = -0.30, 95% CI = -0.51 TO -0.10, P = 0.003, I2 = 0%), 3 MONTHS (SMD = -0.31, 95% CI = -0.45 TO -0.18, P<0.00001, I2 = 30%), 6 MONTHS (SMD = -0.38, 95% CI = -0.53 TO -0.23, P<0.00001, I2 = 0%), 12 MONTHS (SMD = -0.33, 95% CI = -0.54 TO -0.12, P = 0.002, I2 = 9%). THERE WAS NO SIGNIFICANT DIFFERENCE ON PAIN, DISABILITY COMPARED WITH PHYSICAL THERAPY EXERCISE GROUP. FURTHERMORE, IT SUGGESTED THAT THERE WAS A NON-SIGNIFICANT DIFFERENCE ON PHYSICAL AND MENTAL QUALITY OF LIFE BETWEEN YOGA AND ANY OTHER INTERVENTIONS. CONCLUSION: THIS META-ANALYSIS PROVIDED EVIDENCE FROM VERY LOW TO MODERATE INVESTIGATING THE EFFECTIVENESS OF YOGA FOR CHRONIC LOW BACK PAIN PATIENTS AT DIFFERENT TIME POINTS. YOGA MIGHT DECREASE PAIN FROM SHORT TERM TO INTERMEDIATE TERM AND IMPROVE FUNCTIONAL DISABILITY STATUS FROM SHORT TERM TO LONG TERM COMPARED WITH NON-EXERCISE (E.G. USUAL CARE, EDUCATION). YOGA HAD THE SAME EFFECT ON PAIN AND DISABILITY AS ANY OTHER EXERCISE OR PHYSICAL THERAPY. YOGA MIGHT NOT IMPROVE THE PHYSICAL AND MENTAL QUALITY OF LIFE BASED ON THE RESULT OF A MERGING. 2020 9 451 39 CHANGES IN FATIGUE, AUTONOMIC FUNCTIONS, AND BLOOD BIOMARKERS DUE TO SITTING ISOMETRIC YOGA IN PATIENTS WITH CHRONIC FATIGUE SYNDROME. BACKGROUND: IN A PREVIOUS RANDOMIZED CONTROLLED TRIAL, WE FOUND THAT SITTING ISOMETRIC YOGA IMPROVES FATIGUE IN PATIENTS WITH CHRONIC FATIGUE SYNDROME (CFS) WHO ARE RESISTANT TO CONVENTIONAL THERAPY. THE AIM OF THIS STUDY WAS TO INVESTIGATE POSSIBLE MECHANISMS BEHIND THIS FINDING, FOCUSING ON THE SHORT-TERM FATIGUE-RELIEVING EFFECT, BY COMPARING AUTONOMIC NERVOUS FUNCTION AND BLOOD BIOMARKERS BEFORE AND AFTER A SESSION OF ISOMETRIC YOGA. METHODS: FIFTEEN PATIENTS WITH CFS WHO REMAINED SYMPTOMATIC DESPITE AT LEAST 6 MONTHS OF CONVENTIONAL THERAPY PRACTICED SITTING ISOMETRIC YOGA (BIWEEKLY 20 MIN PRACTICE WITH A YOGA INSTRUCTOR AND DAILY HOME PRACTICE) FOR EIGHT WEEKS. ACUTE EFFECTS OF SITTING ISOMETRIC YOGA ON FATIGUE, AUTONOMIC FUNCTION, AND BLOOD BIOMARKERS WERE INVESTIGATED AFTER THE FINAL SESSION WITH AN INSTRUCTOR. THE EFFECT OF A SINGLE SESSION OF SITTING ISOMETRIC YOGA ON FATIGUE WAS ASSESSED BY THE PROFILE OF MOOD STATUS (POMS) QUESTIONNAIRE IMMEDIATELY BEFORE AND AFTER THE SESSION. AUTONOMIC NERVOUS FUNCTION (HEART RATE (HR) VARIABILITY) AND BLOOD BIOMARKERS (CORTISOL, DHEA-S, TNF-ALPHA, IL-6, IFN-GAMMA, IFN-ALPHA, PROLACTIN, CARNITINE, TGF-BETA1, BDNF, MHPG, AND HVA) WERE COMPARED BEFORE AND AFTER THE SESSION. RESULTS: SITTING ISOMETRIC YOGA SIGNIFICANTLY REDUCED THE POMS FATIGUE SCORE (P < 0.01) AND INCREASED THE VIGOR SCORE (P < 0.01). IT ALSO REDUCED HR (P < 0.05) AND INCREASED THE HIGH FREQUENCY POWER (P < 0.05) OF HR VARIABILITY. SITTING ISOMETRIC YOGA INCREASED SERUM LEVELS OF DHEA-S (P < 0.05), REDUCED LEVELS OF CORTISOL (P < 0.05) AND TNF-ALPHA (P < 0.05), AND HAD A TENDENCY TO REDUCE SERUM LEVELS OF PROLACTIN (P < 0.1). DECREASES IN FATIGUE SCORES CORRELATED WITH CHANGES IN PLASMA LEVELS OF TGF-BETA1 AND BDNF. IN CONTRAST, INCREASED VIGOR POSITIVELY CORRELATED WITH HVA. CONCLUSIONS: A SINGLE SESSION OF SITTING ISOMETRIC YOGA REDUCED FATIGUE AND INCREASED VIGOR IN PATIENTS WITH CFS. YOGA ALSO INCREASED VAGAL NERVE FUNCTION AND CHANGED BLOOD BIOMARKERS IN A PATTERN THAT SUGGESTED ANTI-STRESS AND ANTI-INFLAMMATORY EFFECTS. THESE CHANGES APPEAR TO BE RELATED TO THE SHORT-TERM FATIGUE-RELIEVING EFFECT OF SITTING ISOMETRIC YOGA IN PATIENTS WITH CFS. FURTHERMORE, DOPAMINERGIC NERVOUS SYSTEM ACTIVATION MIGHT ACCOUNT FOR SITTING ISOMETRIC YOGA-INDUCED INCREASES IN ENERGY IN THIS PATIENT POPULATION. TRIAL REGISTRATION: UNIVERSITY HOSPITAL MEDICAL INFORMATION NETWORK (UMIN CTR) UMIN000009646. REGISTERED DEC 27, 2012. 2018 10 881 38 EFFECT OF YOGA TRAINING ON INFLAMMATORY CYTOKINES AND C-REACTIVE PROTEIN IN EMPLOYEES OF SMALL-SCALE INDUSTRIES. OBJECTIVE: THE PRESENT STUDY INTENDS TO SEE THE EFFECT OF YOGA PRACTICES ON LIPID PROFILE, INTERLEUKIN (IL)-6, TUMOR NECROSIS FACTOR (TNF)-ALPHA, AND HIGH-SENSITIVITY-C-REACTIVE PROTEIN (HS-CRP) AMONG APPARENTLY HEALTHY ADULTS EXPOSED TO OCCUPATIONAL HAZARDS. MATERIALS AND METHODS: IN THE PRESENT STUDY, 48 PARTICIPANTS AGED 30-58 YEARS (41.5 +/- 5.2) WHO WERE EXPOSED TO OCCUPATIONAL HAZARDS WERE RANDOMIZED INTO TWO GROUPS, THAT IS, EXPERIMENTAL AND WAIT-LIST CONTROL. ALL THE PARTICIPANTS WERE ASSESSED FOR LIPID PROFILE, IL-6, TNF-ALPHA, AND HS-CRP AT THE BASELINE AND AFTER COMPLETION OF 3 MONTHS OF YOGA TRAINING INTERVENTION. THE EXPERIMENTAL GROUP UNDERWENT YOGA TRAINING INTERVENTION FOR 1 H FOR 6 DAYS A WEEK FOR 3 MONTHS, WHEREAS CONTROL GROUP CONTINUED WITH THEIR DAILY ACTIVITIES EXCEPT YOGA TRAINING. DATA ANALYSIS WAS DONE USING STATISTICAL SOFTWARE SPSS VERSION 20.0. DATA WERE ANALYZED USING PAIRED T-TESTS AND INDEPENDENT T-TEST. RESULTS: THE RESULTS OF WITHIN GROUP COMPARISON REVEALED HIGHLY SIGNIFICANT CHANGES IN CHOLESTEROL (P < 0.001), HIGH-DENSITY LIPOPROTEIN (P < 0.001), LOW-DENSITY LIPOPROTEIN (LDL)(P < 0.01), HS-CRP (P < 0.01), IL-6 (P < 0.001), AND TNF-ALPHA (P < 0.001) IN EXPERIMENTAL GROUP. COMPARISON BETWEEN EXPERIMENTAL AND CONTROL GROUP REVEALED SIGNIFICANT CHANGES IN CHOLESTEROL (P < 0.01), LDL (P < 0.05), IL-6 (P < 0.01), TNF-ALPHA (P < 0.01), AND HS-CRP (P < 0.01). CONCLUSION: A YOGA-BASED LIFESTYLE INTERVENTION SEEMS TO BE A HIGHLY PROMISING ALTERNATIVE THERAPY WHICH FAVORABLY ALTERS INFLAMMATORY MARKERS AND METABOLIC RISK FACTORS. 2017 11 2820 52 YOGA TREATMENT FOR CHRONIC NON-SPECIFIC LOW BACK PAIN (2017). WIELAND LS, SKOETZ N, PILKINGTON K, VEMPATI R, DADAMO CR, BERMAN BM. YOGA TREATMENT FOR CHRONIC NON-SPECIFIC LOW BACK PAIN.COCHRANE DATABASE SYST REV2017, ISSUE 1. ART. NO.: CD010671. DOI: 10.1002/14651858.CD010671.PUB2. BACKGROUND: NON-SPECIFIC LOW BACK PAIN IS A COMMON, POTENTIALLY DISABLING CONDITION USUALLY TREATED WITH SELF-CARE AND NON-PRESCRIPTION MEDICATION. FOR CHRONIC LOW BACK PAIN, CURRENT GUIDELINES STATE THAT EXERCISE THERAPY MAY BE BENEFICIAL. YOGA IS A MIND-BODY EXERCISE SOMETIMES USED FOR NON-SPECIFIC LOW BACK PAIN. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA FOR TREATING CHRONIC NON-SPECIFIC LOW BACK PAIN, COMPARED TO NO SPECIFIC TREATMENT, A MINIMAL INTERVENTION (E.G., EDUCATION), OR ANOTHER ACTIVE TREATMENT, WITH A FOCUS ON PAIN, FUNCTION, AND ADVERSE EVENTS. SEARCH METHODS: WE SEARCHED CENTRAL, MEDLINE, EMBASE, FIVE OTHER DATABASES, AND FOUR TRIALS REGISTERS TO 11 MARCH 2016 WITHOUT RESTRICTION OF LANGUAGE OR PUBLICATION STATUS. WE SCREENED REFERENCE LISTS AND CONTACTED EXPERTS IN THE FIELD TO IDENTIFY ADDITIONAL STUDIES. SELECTION CRITERIA: WE INCLUDED RANDOMIZED CONTROLLED TRIALS OF YOGA TREATMENT IN PEOPLE WITH CHRONIC NON-SPECIFIC LOW BACK PAIN. WE INCLUDED STUDIES COMPARING YOGA TO ANY OTHER INTERVENTION OR TO NO INTERVENTION. WE ALSO INCLUDED STUDIES COMPARING YOGA AS AN ADJUNCT TO OTHER THERAPIES, VERSUS THOSE OTHER THERAPIES ALONE. DATA COLLECTION AND ANALYSIS: TWO AUTHORS INDEPENDENTLY SCREENED AND SELECTED STUDIES, EXTRACTED OUTCOME DATA, AND ASSESSED RISK OF BIAS. WE CONTACTED STUDY AUTHORS TO OBTAIN MISSING OR UNCLEAR INFORMATION. WE EVALUATED THE OVERALL CERTAINTY OF EVIDENCE USING THE GRADE APPROACH. MAIN RESULTS: WE INCLUDED 12 TRIALS (1080 PARTICIPANTS) CARRIED OUT IN THE USA (SEVEN TRIALS), INDIA (THREE TRIALS), AND THE UK (TWO TRIALS). STUDIES WERE UNFUNDED (ONE TRIAL), FUNDED BY A YOGA INSTITUTION (ONE TRIAL), FUNDED BY NON-PROFIT OR GOVERNMENT SOURCES (SEVEN TRIALS), OR DID NOT REPORT ON FUNDING (THREE TRIALS). MOST TRIALS USED IYENGAR, HATHA, OR VINIYOGA FORMS OF YOGA. THE TRIALS COMPARED YOGA TO NO INTERVENTION OR A NON-EXERCISE INTERVENTION SUCH AS EDUCATION (SEVEN TRIALS), AN EXERCISE INTERVENTION (THREE TRIALS), OR BOTH EXERCISE AND NON-EXERCISE INTERVENTIONS (TWO TRIALS). ALL TRIALS WERE AT HIGH RISK OF PERFORMANCE AND DETECTION BIAS BECAUSE PARTICIPANTS AND PROVIDERS WERE NOT BLINDED TO TREATMENT ASSIGNMENT, AND OUTCOMES WERE SELF-ASSESSED. THEREFORE, WE DOWNGRADED ALL OUTCOMES TO "MODERATE" CERTAINTY EVIDENCE BECAUSE OF RISK OF BIAS, AND WHEN THERE WAS ADDITIONAL SERIOUS RISK OF BIAS, UNEXPLAINED HETEROGENEITY BETWEEN STUDIES, OR THE ANALYSES WERE IMPRECISE, WE DOWNGRADED THE CERTAINTY OF THE EVIDENCE FURTHER. FOR YOGA COMPARED TO NON-EXERCISE CONTROLS (9 TRIALS; 810 PARTICIPANTS), THERE WAS LOW-CERTAINTY EVIDENCE THAT YOGA PRODUCED SMALL TO MODERATE IMPROVEMENTS IN BACK-RELATED FUNCTION AT THREE TO FOUR MONTHS [STANDARDIZED MEAN DIFFERENCE (SMD) = -0.40, 95% CI: -0.66 TO -0.14; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MEAN DIFFERENCE (MD) = -2.18, 95% CI: -3.60 TO -0.76], MODERATE-CERTAINTY EVIDENCE FOR SMALL TO MODERATE IMPROVEMENTS AT SIX MONTHS (SMD = -0.44, 95% CI: -0.66 TO -0.22; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD = -2.15, 95% CI: -3.23 TO -1.08), AND LOW-CERTAINTY EVIDENCE FOR SMALL IMPROVEMENTS AT 12 MONTHS (SMD = -0.26, 95% CI: -0.46 TO -0.05; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD = -1.36, 95% CI: -2.41 TO -0.26). ON A 0-100 SCALE THERE WAS VERY LOW- TO MODERATE-CERTAINTY EVIDENCE THAT YOGA WAS SLIGHTLY BETTER FOR PAIN AT THREE TO FOUR MONTHS (MD = -4.55, 95% CI: -7.04 TO -2.06), SIX MONTHS (MD = -7.81, 95% CI: -13.37 TO -2.25), AND 12 MONTHS (MD = -5.40, 95% CI: -14.50 TO -3.70); HOWEVER, WE PRE-DEFINED CLINICALLY SIGNIFICANT CHANGES IN PAIN AS 15 POINTS OR GREATER AND THIS THRESHOLD WAS NOT MET. BASED ON INFORMATION FROM SIX TRIALS, THERE WAS MODERATE-CERTAINTY EVIDENCE THAT THE RISK OF ADVERSE EVENTS, PRIMARILY INCREASED BACK PAIN, WAS HIGHER IN YOGA THAN IN NON-EXERCISE CONTROLS [RISK DIFFERENCE (RD) = 5%, 95% CI: 2-8%]. FOR YOGA COMPARED TO NON-YOGA EXERCISE CONTROLS (4 TRIALS; 394 PARTICIPANTS), THERE WAS VERY-LOW-CERTAINTY EVIDENCE FOR LITTLE OR NO DIFFERENCE IN BACK-RELATED FUNCTION AT THREE MONTHS (SMD = -0.22, 95% CI: -0.65 TO 0.20; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD = -0.99, 95% CI: -2.87 TO 0.90) AND SIX MONTHS (SMD = -0.20, 95% CI: -0.59 TO 0.19; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD = -0.90, 95% CI: -2.61 TO 0.81), AND NO INFORMATION ON BACK-RELATED FUNCTION AFTER SIX MONTHS. THERE WAS VERY LOW-CERTAINTY EVIDENCE FOR LOWER PAIN ON A 0-100 SCALE AT SEVEN MONTHS (MD = -20.40, 95% CI: -25.48 TO -15.32), AND NO INFORMATION ON PAIN AT THREE MONTHS OR AFTER SEVEN MONTHS. BASED ON INFORMATION FROM THREE TRIALS, THERE WAS LOW-CERTAINTY EVIDENCE FOR NO DIFFERENCE IN THE RISK OF ADVERSE EVENTS BETWEEN YOGA AND NON-YOGA EXERCISE CONTROLS (RD = 1%, 95% CI: -4% TO 6%). FOR YOGA ADDED TO EXERCISE COMPARED TO EXERCISE ALONE (1 TRIAL; 24 PARTICIPANTS), THERE WAS VERY-LOW-CERTAINTY EVIDENCE FOR LITTLE OR NO DIFFERENCE AT 10 WEEKS IN BACK-RELATED FUNCTION (SMD = -0.60, 95% CI: -1.42 TO 0.22; CORRESPONDING TO A CHANGE IN THE OSWESTRY DISABILITY INDEX OF MD = -17.05, 95% CI: -22.96 TO 11.14) OR PAIN ON A 0-100 SCALE (MD = -3.20, 95% CI: -13.76 TO 7.36). THERE WAS NO INFORMATION ON OUTCOMES AT OTHER TIME POINTS. THERE WAS NO INFORMATION ON ADVERSE EVENTS. STUDIES PROVIDED LIMITED EVIDENCE ON RISK OF CLINICAL IMPROVEMENT, MEASURES OF QUALITY OF LIFE, AND DEPRESSION. THERE WAS NO EVIDENCE ON WORK-RELATED DISABILITY. 2017 12 2629 47 YOGA FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE. BACKGROUND: A SEDENTARY LIFESTYLE AND STRESS ARE MAJOR RISK FACTORS FOR CARDIOVASCULAR DISEASE (CVD). SINCE YOGA INVOLVES EXERCISE AND IS THOUGHT TO HELP IN STRESS REDUCTION IT MAY BE AN EFFECTIVE STRATEGY IN THE PRIMARY PREVENTION OF CVD. OBJECTIVES: TO DETERMINE THE EFFECT OF ANY TYPE OF YOGA ON THE PRIMARY PREVENTION OF CVD. SEARCH METHODS: WE SEARCHED THE FOLLOWING ELECTRONIC DATABASES: THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL) (2013, ISSUE 11) IN THE COCHRANE LIBRARY; MEDLINE (OVID) (1946 TO NOVEMBER WEEK 3 2013); EMBASE CLASSIC + EMBASE (OVID) (1947 TO 2013 WEEK 48); WEB OF SCIENCE (THOMSON REUTERS) (1970 TO 4 DECEMBER 2013); DATABASE OF ABSTRACTS OF REVIEWS OF EFFECTS (DARE), HEALTH TECHNOLOGY ASSESSMENT DATABASE AND HEALTH ECONOMICS EVALUATIONS DATABASE (ISSUE 4 OF 4, 2013) IN THE COCHRANE LIBRARY. WE ALSO SEARCHED A NUMBER OF ASIAN DATABASES AND THE ALLIED AND COMPLEMENTARY MEDICINE DATABASE (AMED) (INCEPTION TO DECEMBER 2012). WE SEARCHED TRIAL REGISTERS AND REFERENCE LISTS OF REVIEWS AND ARTICLES, AND APPROACHED EXPERTS IN THE FIELD. WE APPLIED NO LANGUAGE RESTRICTIONS. SELECTION CRITERIA: RANDOMISED CONTROLLED TRIALS LASTING AT LEAST THREE MONTHS INVOLVING HEALTHY ADULTS OR THOSE AT HIGH RISK OF CVD. TRIALS EXAMINED ANY TYPE OF YOGA AND THE COMPARISON GROUP WAS NO INTERVENTION OR MINIMAL INTERVENTION. OUTCOMES OF INTEREST WERE CLINICAL CVD EVENTS AND MAJOR CVD RISK FACTORS. WE DID NOT INCLUDE ANY TRIALS THAT INVOLVED MULTIFACTORIAL LIFESTYLE INTERVENTIONS OR WEIGHT LOSS. DATA COLLECTION AND ANALYSIS: TWO AUTHORS INDEPENDENTLY SELECTED TRIALS FOR INCLUSION, EXTRACTED DATA AND ASSESSED THE RISK OF BIAS. MAIN RESULTS: WE IDENTIFIED 11 TRIALS (800 PARTICIPANTS) AND TWO ONGOING STUDIES. STYLE AND DURATION OF YOGA DIFFERED BETWEEN TRIALS. HALF OF THE PARTICIPANTS RECRUITED TO THE STUDIES WERE AT HIGH RISK OF CVD. MOST OF STUDIES WERE AT RISK OF PERFORMANCE BIAS, WITH INADEQUATE DETAILS REPORTED IN MANY OF THEM TO JUDGE THE RISK OF SELECTION BIAS.NO STUDY REPORTED CARDIOVASCULAR MORTALITY, ALL-CAUSE MORTALITY OR NON-FATAL EVENTS, AND MOST STUDIES WERE SMALL AND SHORT-TERM. THERE WAS SUBSTANTIAL HETEROGENEITY BETWEEN STUDIES MAKING IT IMPOSSIBLE TO COMBINE STUDIES STATISTICALLY FOR SYSTOLIC BLOOD PRESSURE AND TOTAL CHOLESTEROL. YOGA WAS FOUND TO PRODUCE REDUCTIONS IN DIASTOLIC BLOOD PRESSURE (MEAN DIFFERENCE (MD) -2.90 MMHG, 95% CONFIDENCE INTERVAL (CI) -4.52 TO -1.28), WHICH WAS STABLE ON SENSITIVITY ANALYSIS, TRIGLYCERIDES (MD -0.27 MMOL/L, 95% CI -0.44 TO -0.11) AND HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL (MD 0.08 MMOL/L, 95% CI 0.02 TO 0.14). HOWEVER, THE CONTRIBUTING STUDIES WERE SMALL, SHORT-TERM AND AT UNCLEAR OR HIGH RISK OF BIAS. THERE WAS NO CLEAR EVIDENCE OF A DIFFERENCE BETWEEN GROUPS FOR LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL (MD -0.09 MMOL/L, 95% CI -0.48 TO 0.30), ALTHOUGH THERE WAS MODERATE STATISTICAL HETEROGENEITY. ADVERSE EVENTS, OCCURRENCE OF TYPE 2 DIABETES AND COSTS WERE NOT REPORTED IN ANY OF THE INCLUDED STUDIES. QUALITY OF LIFE WAS MEASURED IN THREE TRIALS BUT THE RESULTS WERE INCONCLUSIVE. AUTHORS' CONCLUSIONS: THE LIMITED EVIDENCE COMES FROM SMALL, SHORT-TERM, LOW-QUALITY STUDIES. THERE IS SOME EVIDENCE THAT YOGA HAS FAVOURABLE EFFECTS ON DIASTOLIC BLOOD PRESSURE, HDL CHOLESTEROL AND TRIGLYCERIDES, AND UNCERTAIN EFFECTS ON LDL CHOLESTEROL. THESE RESULTS SHOULD BE CONSIDERED AS EXPLORATORY AND INTERPRETED WITH CAUTION. 2014 13 1018 37 EFFECTS OF SIX MONTHS OF YOGA ON INFLAMMATORY SERUM MARKERS PROGNOSTIC OF RECURRENCE RISK IN BREAST CANCER SURVIVORS. YOGA-BASED EXERCISE HAS PROVEN TO BE BENEFICIAL FOR PRACTITIONERS, INCLUDING CANCER SURVIVORS. THIS STUDY REPORTS ON THE EFFECT ON INFLAMMATORY BIOLOGICAL MARKERS FOR 20 BREAST CANCER SURVIVORS WHO PARTICIPATED IN A SIX-MONTH YOGA-BASED (YE) EXERCISE PROGRAM. RESULTS ARE COMPARED TO A COMPREHENSIVE EXERCISE (CE) PROGRAM GROUP AND A COMPARISON (C) EXERCISE GROUP WHO CHOSE THEIR OWN EXERCISES. "PRE" AND "POST" ASSESSMENTS INCLUDED MEASURES OF ANTHROPOMETRICS, CARDIORESPIRATORY CAPACITY, AND INFLAMMATORY MARKERS INTERLEUKIN 6 (IL-6), INTERLEUKIN 8 (IL-8), TUMOR NECROSIS FACTOR ALPHA (TNFALPHA) AND C-REACTIVE PROTEIN (CRP). DESCRIPTIVE STATISTICS, EFFECT SIZE (D), AND DEPENDENT SAMPLE 'T' TESTS FOR ALL OUTCOME MEASURES WERE CALCULATED FOR THE YE GROUP. SIGNIFICANT IMPROVEMENTS WERE SEEN IN DECREASED % BODY FAT, (-3.00%, D = -0.44, P = <.001) BUT NOT IN CARDIORESPIRATORY CAPACITY OR IN INFLAMMATORY SERUM MARKERS. TO COMPARE YE OUTCOMES WITH THE OTHER TWO GROUPS, A ONE-WAY ANALYSIS OF CO-VARIANCE (ANCOVA) WAS USED, CONTROLLING FOR AGE, BMI, CARDIORESPIRATORY CAPACITY AND SERUM MARKER BASELINE VALUES. WE FOUND NO DIFFERENCES BETWEEN GROUPS. MOREOVER, WE DID NOT SEE SIGNIFICANT CHANGES IN ANY INFLAMMATORY MARKER FOR ANY GROUP. OUR RESULTS SUPPORT THE EFFECTIVENESS OF YOGA-BASED EXERCISE MODIFIED FOR BREAST CANCER SURVIVORS FOR IMPROVING BODY COMPOSITION. LARGER STUDIES ARE NEEDED TO DETERMINE IF THERE ARE SIGNIFICANT CHANGES IN INFLAMMATORY SERUM MARKERS AS A RESULT OF SPECIFIC EXERCISE MODALITIES. 2015 14 521 34 COMPARING YOGA, EXERCISE, AND A SELF-CARE BOOK FOR CHRONIC LOW BACK PAIN: A RANDOMIZED, CONTROLLED TRIAL. BACKGROUND: CHRONIC LOW BACK PAIN IS A COMMON PROBLEM THAT HAS ONLY MODESTLY EFFECTIVE TREATMENT OPTIONS. OBJECTIVE: TO DETERMINE WHETHER YOGA IS MORE EFFECTIVE THAN CONVENTIONAL THERAPEUTIC EXERCISE OR A SELF-CARE BOOK FOR PATIENTS WITH CHRONIC LOW BACK PAIN. DESIGN: RANDOMIZED, CONTROLLED TRIAL. SETTING: A NONPROFIT, INTEGRATED HEALTH CARE SYSTEM. PATIENTS: 101 ADULTS WITH CHRONIC LOW BACK PAIN. INTERVENTION: 12-WEEK SESSIONS OF YOGA OR CONVENTIONAL THERAPEUTIC EXERCISE CLASSES OR A SELF-CARE BOOK. MEASUREMENTS: PRIMARY OUTCOMES WERE BACK-RELATED FUNCTIONAL STATUS (MODIFIED 24-POINT ROLAND DISABILITY SCALE) AND "BOTHERSOMENESS" OF PAIN (11-POINT NUMERICAL SCALE). THE PRIMARY TIME POINT WAS 12 WEEKS. CLINICALLY SIGNIFICANT CHANGE WAS CONSIDERED TO BE 2.5 POINTS ON THE FUNCTIONAL STATUS SCALE AND 1.5 POINTS ON THE BOTHERSOMENESS SCALE. SECONDARY OUTCOMES WERE DAYS OF RESTRICTED ACTIVITY, GENERAL HEALTH STATUS, AND MEDICATION USE. RESULTS: AFTER ADJUSTMENT FOR BASELINE VALUES, BACK-RELATED FUNCTION IN THE YOGA GROUP WAS SUPERIOR TO THE BOOK AND EXERCISE GROUPS AT 12 WEEKS (YOGA VS. BOOK: MEAN DIFFERENCE, -3.4 [95% CI, -5.1 TO - 1.6] [P < 0.001]; YOGA VS. EXERCISE: MEAN DIFFERENCE, -1.8 [CI, -3.5 TO - 0.1] [P = 0.034]). NO SIGNIFICANT DIFFERENCES IN SYMPTOM BOTHERSOMENESS WERE FOUND BETWEEN ANY 2 GROUPS AT 12 WEEKS; AT 26 WEEKS, THE YOGA GROUP WAS SUPERIOR TO THE BOOK GROUP WITH RESPECT TO THIS MEASURE (MEAN DIFFERENCE, -2.2 [CI, -3.2 TO - 1.2]; P < 0.001). AT 26 WEEKS, BACK-RELATED FUNCTION IN THE YOGA GROUP WAS SUPERIOR TO THE BOOK GROUP (MEAN DIFFERENCE, -3.6 [CI, -5.4 TO - 1.8]; P < 0.001). LIMITATIONS: PARTICIPANTS IN THIS STUDY WERE FOLLOWED FOR ONLY 26 WEEKS AFTER RANDOMIZATION. ONLY 1 INSTRUCTOR DELIVERED EACH INTERVENTION. CONCLUSIONS: YOGA WAS MORE EFFECTIVE THAN A SELF-CARE BOOK FOR IMPROVING FUNCTION AND REDUCING CHRONIC LOW BACK PAIN, AND THE BENEFITS PERSISTED FOR AT LEAST SEVERAL MONTHS. 2005 15 871 47 EFFECT OF YOGA THERAPY ON DISEASE ACTIVITY, INFLAMMATORY MARKERS, AND HEART RATE VARIABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. BACKGROUND: RHEUMATOID ARTHRITIS (RA) IS AN IMMUNE-MEDIATED INFLAMMATORY DISEASE. ANTIRHEUMATOID TREATMENT REDUCES DISEASE ACTIVITY AND INFLAMMATION, BUT NOT ALL PATIENTS RESPOND TO TREATMENT. AUTONOMIC DYSFUNCTION IS COMMON IN RA LEADING TO FREQUENT CARDIOVASCULAR COMPLICATIONS. YOGA THERAPY MAY BE USEFUL IN THESE PATIENTS, BUT THERE ARE LITTLE DATA ON THE EFFECT OF YOGA ON DISEASE ACTIVITY, INFLAMMATORY MARKERS, AND HEART RATE VARIABILITY (HRV). OBJECTIVES: THIS STUDY ASSESSED THE EFFECT OF 12-WEEK YOGA THERAPY ON DISEASE ACTIVITY, INFLAMMATORY MARKERS, AND HRV IN PATIENTS WITH RA. MATERIALS AND METHODS: THIS RANDOMIZED CONTROL TRIAL WAS CONDUCTED ON NEWLY DIAGNOSED RA PATIENTS ATTENDING OUTPATIENT SERVICES AT THE DEPARTMENT OF CLINICAL IMMUNOLOGY, JIPMER. ONE HUNDRED AND SIXTY-SIX PARTICIPANTS WERE RANDOMIZED INTO TWO GROUPS: THE CONTROL GROUP (CG) (N = 83) AND YOGA GROUP (YG) (N = 83). YOGA THERAPY WAS ADMINISTERED TO PARTICIPANTS IN THE YG FOR 12 WEEKS, ALONG WITH STANDARD MEDICAL TREATMENT. THE CG RECEIVED ONLY STANDARD MEDICAL TREATMENT. PRIMARY OUTCOMES WERE DISEASE ACTIVITY SCORE 28, INTERLEUKIN-1ALPHA (IL-1ALPHA), IL-6, TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA), CORTISOL, AND HRV PARAMETERS. ALL PARAMETERS WERE MEASURED AT BASELINE AND AFTER 12 WEEKS. RESULTS: DISEASE ACTIVITY SIGNIFICANTLY DECREASED IN BOTH GROUPS AFTER 12 WEEKS, BUT IT WAS REDUCED MORE IN YG, WHICH WAS STATISTICALLY SIGNIFICANT (P < 0.05). IN BOTH YG AND CG, IL-1ALPHA, IL-6, TNF-ALPHA, AND CORTISOL DECREASED AFTER 12 WEEKS, BUT IL-1ALPHA AND CORTISOL DECREASED MORE SIGNIFICANTLY IN YG THAN IN CG. LOW-FREQUENCY COMPONENT EXPRESSED AS NORMALIZED UNIT (LFNU) AND THE LOW-FREQUENCY/HIGH-FREQUENCY (LF-HF) RATIO DECREASED SIGNIFICANTLY, AND TOTAL POWER AND HF COMPONENT EXPRESSED AS NORMALIZED UNIT (HFNU) INCREASED SIGNIFICANTLY IN THE YG COMPARED WITH CG. CONCLUSION: TWELVE-WEEK YOGA THERAPY, IF GIVEN ALONG WITH STANDARD MEDICAL TREATMENT, SIGNIFICANTLY REDUCES DISEASE ACTIVITY AND IMPROVES SYMPATHOVAGAL BALANCE IN RA PATIENTS. 2020 16 2587 52 YOGA FOR IMPROVING HEALTH-RELATED QUALITY OF LIFE, MENTAL HEALTH AND CANCER-RELATED SYMPTOMS IN WOMEN DIAGNOSED WITH BREAST CANCER. BACKGROUND: BREAST CANCER IS THE CANCER MOST FREQUENTLY DIAGNOSED IN WOMEN WORLDWIDE. EVEN THOUGH SURVIVAL RATES ARE CONTINUALLY INCREASING, BREAST CANCER IS OFTEN ASSOCIATED WITH LONG-TERM PSYCHOLOGICAL DISTRESS, CHRONIC PAIN, FATIGUE AND IMPAIRED QUALITY OF LIFE. YOGA COMPRISES ADVICE FOR AN ETHICAL LIFESTYLE, SPIRITUAL PRACTICE, PHYSICAL ACTIVITY, BREATHING EXERCISES AND MEDITATION. IT IS A COMPLEMENTARY THERAPY THAT IS COMMONLY RECOMMENDED FOR BREAST CANCER-RELATED IMPAIRMENTS AND HAS BEEN SHOWN TO IMPROVE PHYSICAL AND MENTAL HEALTH IN PEOPLE WITH DIFFERENT CANCER TYPES. OBJECTIVES: TO ASSESS EFFECTS OF YOGA ON HEALTH-RELATED QUALITY OF LIFE, MENTAL HEALTH AND CANCER-RELATED SYMPTOMS AMONG WOMEN WITH A DIAGNOSIS OF BREAST CANCER WHO ARE RECEIVING ACTIVE TREATMENT OR HAVE COMPLETED TREATMENT. SEARCH METHODS: WE SEARCHED THE COCHRANE BREAST CANCER SPECIALISED REGISTER, MEDLINE (VIA PUBMED), EMBASE, THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL; 2016, ISSUE 1), INDEXING OF INDIAN MEDICAL JOURNALS (INDMED), THE WORLD HEALTH ORGANIZATION (WHO) INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM (ICTRP) SEARCH PORTAL AND CLINICALTRIALS.GOV ON 29 JANUARY 2016. WE ALSO SEARCHED REFERENCE LISTS OF IDENTIFIED RELEVANT TRIALS OR REVIEWS, AS WELL AS CONFERENCE PROCEEDINGS OF THE INTERNATIONAL CONGRESS ON COMPLEMENTARY MEDICINE RESEARCH (ICCMR), THE EUROPEAN CONGRESS FOR INTEGRATIVE MEDICINE (ECIM) AND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). WE APPLIED NO LANGUAGE RESTRICTIONS. SELECTION CRITERIA: RANDOMISED CONTROLLED TRIALS WERE ELIGIBLE WHEN THEY (1) COMPARED YOGA INTERVENTIONS VERSUS NO THERAPY OR VERSUS ANY OTHER ACTIVE THERAPY IN WOMEN WITH A DIAGNOSIS OF NON-METASTATIC OR METASTATIC BREAST CANCER, AND (2) ASSESSED AT LEAST ONE OF THE PRIMARY OUTCOMES ON PATIENT-REPORTED INSTRUMENTS, INCLUDING HEALTH-RELATED QUALITY OF LIFE, DEPRESSION, ANXIETY, FATIGUE OR SLEEP DISTURBANCES. DATA COLLECTION AND ANALYSIS: TWO REVIEW AUTHORS INDEPENDENTLY COLLECTED DATA ON METHODS AND RESULTS. WE EXPRESSED OUTCOMES AS STANDARDISED MEAN DIFFERENCES (SMDS) WITH 95% CONFIDENCE INTERVALS (CIS) AND CONDUCTED RANDOM-EFFECTS MODEL META-ANALYSES. WE ASSESSED POTENTIAL RISK OF PUBLICATION BIAS THROUGH VISUAL ANALYSIS OF FUNNEL PLOT SYMMETRY AND HETEROGENEITY BETWEEN STUDIES BY USING THE CHI(2) TEST AND THE I(2) STATISTIC. WE CONDUCTED SUBGROUP ANALYSES FOR CURRENT TREATMENT STATUS, TIME SINCE DIAGNOSIS, STAGE OF CANCER AND TYPE OF YOGA INTERVENTION. MAIN RESULTS: WE INCLUDED 24 STUDIES WITH A TOTAL OF 2166 PARTICIPANTS, 23 OF WHICH PROVIDED DATA FOR META-ANALYSIS. THIRTEEN STUDIES HAD LOW RISK OF SELECTION BIAS, FIVE STUDIES REPORTED ADEQUATE BLINDING OF OUTCOME ASSESSMENT AND 15 STUDIES HAD LOW RISK OF ATTRITION BIAS.SEVENTEEN STUDIES THAT COMPARED YOGA VERSUS NO THERAPY PROVIDED MODERATE-QUALITY EVIDENCE SHOWING THAT YOGA IMPROVED HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.22, 95% CI 0.04 TO 0.40; 10 STUDIES, 675 PARTICIPANTS), REDUCED FATIGUE (POOLED SMD -0.48, 95% CI -0.75 TO -0.20; 11 STUDIES, 883 PARTICIPANTS) AND REDUCED SLEEP DISTURBANCES IN THE SHORT TERM (POOLED SMD -0.25, 95% CI -0.40 TO -0.09; SIX STUDIES, 657 PARTICIPANTS). THE FUNNEL PLOT FOR HEALTH-RELATED QUALITY OF LIFE WAS ASYMMETRICAL, FAVOURING NO THERAPY, AND THE FUNNEL PLOT FOR FATIGUE WAS ROUGHLY SYMMETRICAL. THIS HINTS AT OVERALL LOW RISK OF PUBLICATION BIAS. YOGA DID NOT APPEAR TO REDUCE DEPRESSION (POOLED SMD -0.13, 95% CI -0.31 TO 0.05; SEVEN STUDIES, 496 PARTICIPANTS; LOW-QUALITY EVIDENCE) OR ANXIETY (POOLED SMD -0.53, 95% CI -1.10 TO 0.04; SIX STUDIES, 346 PARTICIPANTS; VERY LOW-QUALITY EVIDENCE) IN THE SHORT TERM AND HAD NO MEDIUM-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.10, 95% CI -0.23 TO 0.42; TWO STUDIES, 146 PARTICIPANTS; LOW-QUALITY EVIDENCE) OR FATIGUE (POOLED SMD -0.04, 95% CI -0.36 TO 0.29; TWO STUDIES, 146 PARTICIPANTS; LOW-QUALITY EVIDENCE). INVESTIGATORS REPORTED NO SERIOUS ADVERSE EVENTS.FOUR STUDIES THAT COMPARED YOGA VERSUS PSYCHOSOCIAL/EDUCATIONAL INTERVENTIONS PROVIDED MODERATE-QUALITY EVIDENCE INDICATING THAT YOGA CAN REDUCE DEPRESSION (POOLED SMD -2.29, 95% CI -3.97 TO -0.61; FOUR STUDIES, 226 PARTICIPANTS), ANXIETY (POOLED SMD -2.21, 95% CI -3.90 TO -0.52; THREE STUDIES, 195 PARTICIPANTS) AND FATIGUE (POOLED SMD -0.90, 95% CI -1.31 TO -0.50; TWO STUDIES, 106 PARTICIPANTS) IN THE SHORT TERM. VERY LOW-QUALITY EVIDENCE SHOWED NO SHORT-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.81, 95% CI -0.50 TO 2.12; TWO STUDIES, 153 PARTICIPANTS) OR SLEEP DISTURBANCES (POOLED SMD -0.21, 95% CI -0.76 TO 0.34; TWO STUDIES, 119 PARTICIPANTS). NO TRIAL ADEQUATELY REPORTED SAFETY-RELATED DATA.THREE STUDIES THAT COMPARED YOGA VERSUS EXERCISE PRESENTED VERY LOW-QUALITY EVIDENCE SHOWING NO SHORT-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD -0.04, 95% CI -0.30 TO 0.23; THREE STUDIES, 233 PARTICIPANTS) OR FATIGUE (POOLED SMD -0.21, 95% CI -0.66 TO 0.25; THREE STUDIES, 233 PARTICIPANTS); NO TRIAL PROVIDED SAFETY-RELATED DATA. AUTHORS' CONCLUSIONS: MODERATE-QUALITY EVIDENCE SUPPORTS THE RECOMMENDATION OF YOGA AS A SUPPORTIVE INTERVENTION FOR IMPROVING HEALTH-RELATED QUALITY OF LIFE AND REDUCING FATIGUE AND SLEEP DISTURBANCES WHEN COMPARED WITH NO THERAPY, AS WELL AS FOR REDUCING DEPRESSION, ANXIETY AND FATIGUE, WHEN COMPARED WITH PSYCHOSOCIAL/EDUCATIONAL INTERVENTIONS. VERY LOW-QUALITY EVIDENCE SUGGESTS THAT YOGA MIGHT BE AS EFFECTIVE AS OTHER EXERCISE INTERVENTIONS AND MIGHT BE USED AS AN ALTERNATIVE TO OTHER EXERCISE PROGRAMMES. 2017 17 2543 58 YOGA FOR ASTHMA. BACKGROUND: ASTHMA IS A COMMON CHRONIC INFLAMMATORY DISORDER AFFECTING ABOUT 300 MILLION PEOPLE WORLDWIDE. AS A HOLISTIC THERAPY, YOGA HAS THE POTENTIAL TO RELIEVE BOTH THE PHYSICAL AND PSYCHOLOGICAL SUFFERING OF PEOPLE WITH ASTHMA, AND ITS POPULARITY HAS EXPANDED GLOBALLY. A NUMBER OF CLINICAL TRIALS HAVE BEEN CARRIED OUT TO EVALUATE THE EFFECTS OF YOGA PRACTICE, WITH INCONSISTENT RESULTS. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA IN PEOPLE WITH ASTHMA. SEARCH METHODS: WE SYSTEMATICALLY SEARCHED THE COCHRANE AIRWAYS GROUP REGISTER OF TRIALS, WHICH IS DERIVED FROM SYSTEMATIC SEARCHES OF BIBLIOGRAPHIC DATABASES INCLUDING THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, AND PSYCINFO, AND HANDSEARCHING OF RESPIRATORY JOURNALS AND MEETING ABSTRACTS. WE ALSO SEARCHED PEDRO. WE SEARCHED CLINICALTRIALS.GOV AND THE WHO ICTRP SEARCH PORTAL. WE SEARCHED ALL DATABASES FROM THEIR INCEPTION TO 22 JULY 2015, AND USED NO RESTRICTION ON LANGUAGE OF PUBLICATION. WE CHECKED THE REFERENCE LISTS OF ELIGIBLE STUDIES AND RELEVANT REVIEW ARTICLES FOR ADDITIONAL STUDIES. WE ATTEMPTED TO CONTACT INVESTIGATORS OF ELIGIBLE STUDIES AND EXPERTS IN THE FIELD TO LEARN OF OTHER PUBLISHED AND UNPUBLISHED STUDIES. SELECTION CRITERIA: WE INCLUDED RANDOMISED CONTROLLED TRIALS (RCTS) THAT COMPARED YOGA WITH USUAL CARE (OR NO INTERVENTION) OR SHAM INTERVENTION IN PEOPLE WITH ASTHMA AND REPORTED AT LEAST ONE OF THE FOLLOWING OUTCOMES: QUALITY OF LIFE, ASTHMA SYMPTOM SCORE, ASTHMA CONTROL, LUNG FUNCTION MEASURES, ASTHMA MEDICATION USAGE, AND ADVERSE EVENTS. DATA COLLECTION AND ANALYSIS: WE EXTRACTED BIBLIOGRAPHIC INFORMATION, CHARACTERISTICS OF PARTICIPANTS, CHARACTERISTICS OF INTERVENTIONS AND CONTROLS, CHARACTERISTICS OF METHODOLOGY, AND RESULTS FOR THE OUTCOMES OF OUR INTEREST FROM ELIGIBLE STUDIES. FOR CONTINUOUS OUTCOMES, WE USED MEAN DIFFERENCE (MD) WITH 95% CONFIDENCE INTERVAL (CI) TO DENOTE THE TREATMENT EFFECTS, IF THE OUTCOMES WERE MEASURED BY THE SAME SCALE ACROSS STUDIES. ALTERNATIVELY, IF THE OUTCOMES WERE MEASURED BY DIFFERENT SCALES ACROSS STUDIES, WE USED STANDARDISED MEAN DIFFERENCE (SMD) WITH 95% CI. FOR DICHOTOMOUS OUTCOMES, WE USED RISK RATIO (RR) WITH 95% CI TO MEASURE THE TREATMENT EFFECTS. WE PERFORMED META-ANALYSIS WITH REVIEW MANAGER 5.3. WE USED THE FIXED-EFFECT MODEL TO POOL THE DATA, UNLESS THERE WAS SUBSTANTIAL HETEROGENEITY AMONG STUDIES, IN WHICH CASE WE USED THE RANDOM-EFFECTS MODEL INSTEAD. FOR OUTCOMES INAPPROPRIATE OR IMPOSSIBLE TO POOL QUANTITATIVELY, WE CONDUCTED A DESCRIPTIVE ANALYSIS AND SUMMARISED THE FINDINGS NARRATIVELY. MAIN RESULTS: WE INCLUDED 15 RCTS WITH A TOTAL OF 1048 PARTICIPANTS. MOST OF THE TRIALS WERE CONDUCTED IN INDIA, FOLLOWED BY EUROPE AND THE UNITED STATES. THE MAJORITY OF PARTICIPANTS WERE ADULTS OF BOTH SEXES WITH MILD TO MODERATE ASTHMA FOR SIX MONTHS TO MORE THAN 23 YEARS. FIVE STUDIES INCLUDED YOGA BREATHING ALONE, WHILE THE OTHER STUDIES ASSESSED YOGA INTERVENTIONS THAT INCLUDED BREATHING, POSTURE, AND MEDITATION. INTERVENTIONS LASTED FROM TWO WEEKS TO 54 MONTHS, FOR NO MORE THAN SIX MONTHS IN THE MAJORITY OF STUDIES. THE RISK OF BIAS WAS LOW ACROSS ALL DOMAINS IN ONE STUDY AND UNCLEAR OR HIGH IN AT LEAST ONE DOMAIN FOR THE REMAINDER.THERE WAS SOME EVIDENCE THAT YOGA MAY IMPROVE QUALITY OF LIFE (MD IN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) SCORE PER ITEM 0.57 UNITS ON A 7-POINT SCALE, 95% CI 0.37 TO 0.77; 5 STUDIES; 375 PARTICIPANTS), IMPROVE SYMPTOMS (SMD 0.37, 95% CI 0.09 TO 0.65; 3 STUDIES; 243 PARTICIPANTS), AND REDUCE MEDICATION USAGE (RR 5.35, 95% CI 1.29 TO 22.11; 2 STUDIES) IN PEOPLE WITH ASTHMA. THE MD FOR AQLQ SCORE EXCEEDED THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE (MCID) OF 0.5, BUT WHETHER THE MEAN CHANGES EXCEEDED THE MCID FOR ASTHMA SYMPTOMS IS UNCERTAIN DUE TO THE LACK OF AN ESTABLISHED MCID IN THE SEVERITY SCORES USED IN THE INCLUDED STUDIES. THE EFFECTS OF YOGA ON CHANGE FROM BASELINE FORCED EXPIRATORY VOLUME IN ONE SECOND (MD 0.04 LITRES, 95% CI -0.10 TO 0.19; 7 STUDIES; 340 PARTICIPANTS; I(2) = 68%) WERE NOT STATISTICALLY SIGNIFICANT. TWO STUDIES INDICATED IMPROVED ASTHMA CONTROL, BUT DUE TO VERY SIGNIFICANT HETEROGENEITY (I(2) = 98%) WE DID NOT POOL DATA. NO SERIOUS ADVERSE EVENTS ASSOCIATED WITH YOGA WERE REPORTED, BUT THE DATA ON THIS OUTCOME WAS LIMITED. AUTHORS' CONCLUSIONS: WE FOUND MODERATE-QUALITY EVIDENCE THAT YOGA PROBABLY LEADS TO SMALL IMPROVEMENTS IN QUALITY OF LIFE AND SYMPTOMS IN PEOPLE WITH ASTHMA. THERE IS MORE UNCERTAINTY ABOUT POTENTIAL ADVERSE EFFECTS OF YOGA AND ITS IMPACT ON LUNG FUNCTION AND MEDICATION USAGE. RCTS WITH A LARGE SAMPLE SIZE AND HIGH METHODOLOGICAL AND REPORTING QUALITY ARE NEEDED TO CONFIRM THE EFFECTS OF YOGA FOR ASTHMA. 2016 18 811 38 EFFECT OF YOGA ON BLOOD PRESSURE IN PREHYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS. INTRODUCTION: PREHYPERTENSION IS A PRECURSOR FOR DEVELOPING HYPERTENSION AND IS A RISK FACTOR FOR CARDIOVASCULAR DISEASES. YOGA THERAPY MAY HAVE A ROLE IN LOWERING THE BLOOD PRESSURES IN PREHYPERTENSION AND HYPERTENSION. THIS SYSTEMATIC REVIEW AIMS TO SYNTHESIZE THE AVAILABLE LITERATURE FOR THE SAME. METHODOLOGY. DATABASES SUCH AS PUBMED, EMBASE, SCOPUS, AND WEB OF SCIENCE WERE SEARCHED FOR RANDOMISED CONTROL TRIALS ONLY IN THE TIME DURATION OF 2010-2021. THE MAIN OUTCOME OF INTEREST WAS SYSTOLIC AND DIASTOLIC BLOOD PRESSURES. ARTICLES WERE SCREENED BASED ON THE INCLUSION CRITERIA, AND 8 ARTICLES WERE RECRUITED FOR THE REVIEW. META-ANALYSIS WAS DONE FOR SUITABLE ARTICLES. REVMAN 5.4 BY COCHRANE WAS USED FOR META-ANALYSIS AND FOREST PLOT CONSTRUCTION. RISK OF BIAS WAS DETERMINED USING THE DOWNS AND BLACK CHECKLIST BY THREE INDEPENDENT AUTHORS. RESULTS: THE META-ANALYSIS OF THE ARTICLES FAVOURED YOGA INTERVENTION OVER THE CONTROL INTERVENTION. YOGA THERAPY HAD SIGNIFICANTLY REDUCED THE SYSTOLIC PRESSURE (-0.62 STANDARD MEAN DIFFERENCE, AT IV FIXED 95% CI: -0.83, -0.41) AND DIASTOLIC PRESSURE (-0.81 STANDARD MEAN DIFFERENCE, AT IV RANDOM 95% CI: -1.39, -0.22). SECONDARY OUTCOME MEASURES STUDIED WERE HEART RATE, WEIGHT, BMI, WAIST CIRCUMFERENCE, AND LIPID PROFILE. THE MAIN PROTOCOL OF YOGA THERAPY INCLUDED POSTURES, BREATHING EXERCISES, AND DIFFERENT MEDITATION TECHNIQUES. A SIGNIFICANT REDUCTION IN SECONDARY OUTCOMES WAS OBSERVED, EXCEPT FOR HDL VALUES IN LIPID PROFILE WHICH SHOWED A GRADUAL INCREASE IN YOGA GROUP IN COMPARISON WITH ALTERNATIVE THERAPY. CONCLUSION: YOGA THERAPY HAS SHOWN TO BE SIGNIFICANT IN THE REDUCTION OF SYSTOLIC AND DIASTOLIC PRESSURE IN PREHYPERTENSIVE POPULATION. SUPPORTING EVIDENCE LACKS IN PROVIDING A PROPER STRUCTURED DOSAGE OF YOGA ASANAS AND BREATHING TECHNIQUES. CONSIDERING THE EXISTING LITERATURE AND EVIDENCE, YOGA THERAPY CAN BE USED AND RECOMMENDED IN PREHYPERTENSIVE POPULATION AND CAN BE BENEFICIAL IN REDUCING THE CHANCES OF DEVELOPING HYPERTENSION OR CARDIOVASCULAR DISEASES. 2021 19 90 46 A MODIFIED YOGA-BASED EXERCISE PROGRAM IN HEMODIALYSIS PATIENTS: A RANDOMIZED CONTROLLED STUDY. AIM: TO EVALUATE THE EFFECTS OF A YOGA-BASED EXERCISE PROGRAM ON PAIN, FATIGUE, SLEEP DISTURBANCE, AND BIOCHEMICAL MARKERS IN HEMODIALYSIS PATIENTS. MATERIALS AND METHODS: IN 2004 A RANDOMIZED CONTROLLED TRIAL WAS CARRIED OUT IN THE OUTPATIENT HEMODIALYSIS UNIT OF THE NEPHROLOGY DEPARTMENT, ULUDAG UNIVERSITY FACULTY OF MEDICINE. CLINICALLY STABLE HEMODIALYSIS PATIENTS (N=37) WERE INCLUDED AND FOLLOWED IN TWO GROUPS: THE MODIFIED YOGA-BASED EXERCISE GROUP (N=19) AND THE CONTROL GROUP (N=18). YOGA-BASED EXERCISES WERE DONE IN GROUPS FOR 30 MIN/DAY TWICE A WEEK FOR 3 MONTHS. ALL OF THE PATIENTS IN THE YOGA AND CONTROL GROUPS WERE GIVEN AN ACTIVE RANGE OF MOTION EXERCISES TO DO FOR 10 MIN AT HOME. THE MAIN OUTCOME MEASURES WERE PAIN INTENSITY (MEASURED BY THE VISUAL ANALOGUE SCALE, VAS), FATIGUE (VAS), SLEEP DISTURBANCE (VAS), AND GRIP STRENGTH (MMHG); BIOCHEMICAL VARIABLES-- UREA, CREATININE, CALCIUM, ALKALINE PHOSPHATASE, PHOSPHORUS, CHOLESTEROL, HDL-CHOLESTEROL, TRIGLYCERIDE, ERYTHROCYTE, HEMATOCRIT--WERE EVALUATED. RESULTS: AFTER A 12-WEEK INTERVENTION, SIGNIFICANT IMPROVEMENTS WERE SEEN IN THE VARIABLES: PAIN -37%, FATIGUE -55%, SLEEP DISTURBANCE -25%, GRIP STRENGTH +15%, UREA -29%, CREATININE -14%, ALKALINE PHOSPHATASE -15%, CHOLESTEROL -15%, ERYTHROCYTE +11%, AND HEMATOCRIT COUNT +13%; NO SIDE-EFFECTS WERE SEEN. IMPROVEMENT OF THE VARIABLES IN THE YOGA-BASED EXERCISE PROGRAM WAS FOUND TO BE SUPERIOR TO THAT IN THE CONTROL GROUP FOR ALL THE VARIABLES EXCEPT CALCIUM, PHOSPHORUS, HDL-CHOLESTEROL AND TRIGLYCERIDE LEVELS. CONCLUSION: A SIMPLIFIED YOGA-BASED REHABILITATION PROGRAM IS A COMPLEMENTARY, SAFE AND EFFECTIVE CLINICAL TREATMENT MODALITY IN PATIENTS WITH END-STAGE RENAL DISEASE. 2007 20 859 38 EFFECT OF YOGA PRACTICE ON LEVELS OF INFLAMMATORY MARKERS AFTER MODERATE AND STRENUOUS EXERCISE. BACKGROUND AND OBJECTIVES: TO EVALUATE THE EFFECT OF YOGA PRACTICE AND EXERCISE CHALLENGE ON TUMOUR NECROSIS FACTOR ALPHA (TNF-ALPHA), INTERLEUKIN-6 (IL-6) LEVELS AND LIPID PROFILE. MATERIALS AND METHODS: TWO HUNDRED AND EIGHTEEN SUBJECTS PARTICIPATED IN THE STUDY. ONE HUNDRED AND NINE VOLUNTEERS (51 MALES AND 58 FEMALES) IN THE AGE GROUP OF 20 TO 60 YEARS, WHO PRACTICED YOGA REGULARLY FOR OVER FIVE YEARS FOR A PERIOD OF ONE HOUR DAILY, PERFORMED A BOUT OF MODERATE EXERCISE AND A BOUT OF STRENUOUS EXERCISE AS PER STANDARDIZED SHUTTLE WALK TEST PROTOCOL. ANTHROPOMETRICALLY MATCHED, AGE MATCHED AND GENDER MATCHED SUBJECTS, WHO DID NOT PRACTICE YOGA (NON-YOGA GROUP) WERE CHOSEN AS CONTROLS (NON-YOGA, N=109). THE NON-YOGA GROUP ALSO PERFORMED SIMILAR EXERCISES. THE BLOOD SAMPLES OF BOTH THE GROUPS WERE COLLECTED BEFORE AND AFTER THE EXERCISES. TNF-ALPHA AND IL-6 WAS ANALYSED BEFORE AND AFTER THE EXERCISE BY SANDWICH ELISA (ENZYME LINKED IMMUNOSORBENT ASSAY). RESULTS: RESTING PLASMA TNF-ALPHA CONCENTRATION WAS SIGNIFICANTLY HIGHER IN NON-YOGA GROUP WHEN COMPARED TO YOGA GROUP (P<0.05). THERE WAS AN INCREASE IN TNF-ALPHA LEVELS IN BOTH THE GROUPS IN RESPONSE TO STRENUOUS EXERCISE. THERE WAS NO GENDER DIFFERENCE IN TNF-ALPHA AND IL-6 LEVELS BEFORE AND AFTER EXERCISE IN YOGA AND NON-YOGA GROUPS. CONCLUSION: REGULAR PRACTICE OF YOGA LOWERS BASAL TNF-ALPHA AND IL-6 LEVELS. IT ALSO REDUCES THE EXTENT OF INCREASE OF TNF-ALPHA AND IL-6 TO A PHYSICAL CHALLENGE OF MODERATE EXERCISE AND STRENUOUS EXERCISE. THERE IS NO SIGNIFICANT GENDER DIFFERENCE IN THE TNF-ALPHA AND IL-6 LEVELS. REGULAR PRACTICE OF YOGA CAN PROTECT THE INDIVIDUAL AGAINST INFLAMMATORY DISEASES BY FAVOURABLY ALTERING PRO-INFLAMMATORY CYTOKINE LEVELS. 2015